We work closely with entrepreneurs and investors at the forefront of the global healthcare revolution. Our in-depth sector knowledge, combined with our technical capability, enables us to help corporates and investors capitalise on the enormous opportunities across the sector as they seek to consolidate and grow their market positions.
The ageing population, technological change, and increased demand for healthcare products and services, all create great opportunities in the health and social care, medical devices, life sciences, bioscience and pharmaceutical markets. Our job is to help our clients maximise those opportunities.
Adviser to Palatine Private Equity on its investment in Routes Healthcare
View moreAdviser to PRIMA on its majority sale to Lideta
View moreAdviser to VIGO Health on its investment from Irish Life Group
View moreAdviser to the shareholders of Didactic on the sale of a majority stake of the Group to FCDE
View moreAdviser to Unilabs on the sale of 100% of the share capital of Unilabs Italia Srl. to Lifebrain
View moreAdviser to Naxicap on the acquisition of a majority stake in Laguarrigue from Ardian
View moreAdviser to the shareholders of CVC Capital Partners, 3i and KKR, and Careit on the acquisition of Essling Capital and its financing
View moreAdviser to Sagitta Pharma's shareholder in Isatis Capital's majority LBO
View moreAdviser to the shareholders of Nathura on the sale to Giuliani
View moreAdviser to a Family Office on the acquisition of a majority stake in 3 Chênes
Adviser to PHMR Ltd on its sale to Ashfield Advisory, part of UDG Healthcare Plc
View moreAdviser to DomusVi on the acquisition of Groupe Les Matines
View moreLuc Bertholat, Partner, Naxicap PartnersClearwater has been very professional in leading the process involving candidates from all over the world.
The team were quickly able to identify the right partner for us and used their excellent relationship with the buyer to help negotiate a transaction that met our objectives.Dan Smart, CEO, Proclinical
With in-depth knowledge and technical capability, our healthcare team has a great track record of delivering tailored solutions.
See our teamOver 65
deals advised upon
in the last 5 years
€9.4bn
in deal value
over the last 5 years
Over 40%
deals involving PE
in the last 5 years
Following the publication of the Q1 2021 Clearwater International Multiples Heatmap, Unquote interviewed Clearwater’s executive team to discuss valuation trends in European private equity.
Read more
With average multiples hitting a record peak, European PE dealmakers appear to have quickly adjusted to the post-pandemic dealmaking environment – delivering record deal value during the first quarter of the year.
Read more
This report identifies key themes driving European Private Equity (PE) deals’ EV/EBITDA multiples on a quarterly basis. Through illustrating key valuation trends across regions and sectors, we aim to support PE investors source better investment opportunities.
Read more
